Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00949 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Shang Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research, Department of Natural Medicinal Chemistry…. Hauptthemen laut MEDLINE: Necroptosis, Protein Kinases, Proteolysis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: ?333 Project? of Jiangsu Province, Double First Class University Plan, Basic Research Program of Jiangsu Province.
Abstract (Originalsprache)
Mixed lineage kinase domain-like pseudokinase (MLKL) initiates necroptosis and could serve as a therapeutic target related to a series of human diseases. Proteolysis-targeting chimeras (PROTACs) are useful tools for degrading pathological proteins and blocking disease processes. Using computer-aided modeling and molecular dynamics simulations, we developed a series of covalent MLKL PROTACs by linking and optimizing a theophylline derivative that covalently targets MLKL. Via structure-activity relationship studies, MP-11 was identified as a potent MLKL PROTAC degrader. Furthermore, MP-11 showed lower toxicity than the original MLKL ligand, exhibiting nanomolar-scale antinecroptotic activity on human cell lines. Xenograft model studies showed that MP-11 effectively degraded MLKL in vivo. Importantly, our study demonstrates that the covalent binding strategy is an effective approach for designing MLKL-targeting PROTACs, serving as a model for developing PROTACs to treat future necroptosis-related human diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.
ORCID-Profile: Shang Li, Fucheng Yin, Yifan Chen, Lingyi Kong, Xiaobing Wang
Förderung
- ?333 Project? of Jiangsu Province
- Double First Class University Plan
- Basic Research Program of Jiangsu Province
- Six Talent Peaks Project in Jiangsu Province
- Higher Education Discipline Innovation Project
- Jiangsu Scientific Research and Practice Innovation Project
Zitieren
APA
Li, S., Ma, L., Li, X., Jiang, Y., Luo, Z., Yin, F., Zhang, Y., Chen, Y., Wan, S., Zhou, H., Kong, L., & Wang, X. (2024). Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00949
Vancouver
Li S, Ma L, Li X, Jiang Y, Luo Z, Yin F, et al. Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00949
BibTeX
@article{Li2024,
author = {Li, Shang and Ma, Liangliang and Li, Xinxin and Jiang, Yuhan and Luo, Zhongwen and Yin, Fucheng and Zhang, Yonglei and Chen, Yifan and Wan, Siyuan and Zhou, Han and Kong, Lingyi and Wang, Xiaobing},
title = {Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00949}
}
EUVIMED